Results 11 to 20 of about 136,305 (116)

Clinic-based Treatment of Type B Ulnar Polydactyly Saves Costs Compared With Treatment in the Operating Room. [PDF]

Plast Reconstr Surg Glob Open
Singh NP, Yun E, Tran K, Brooks C, Adkinson JM, Borschel GH.   +5 more
europepmc   +1 more source

What Drives Public Preference for Rare Drugs Coverage in China? Insights From a Multi-Center Discrete Choice Experiment. [PDF]

Health Expect
Wu Y, Chen J, Shao J, Peng H, Li L, Chen G, Li S.   +6 more
europepmc   +1 more source

Advancing health technology assessment in Taiwan: over 15 years of evidence-based reform, innovation, and patient partnership. [PDF]

Int J Technol Assess Health Care
Huang LY, Lin SY, Liu MH.
europepmc   +1 more source

Joint Clinical Assessment in the EU HTA Regulation-Would Drugs Supported by Single-Arm Trials Fit Under Evaluation? [PDF]

J Mark Access Health Policy
Kloc K, Toumi M, Łukomska E, Kowalska M, Tyrała-Chowaniec I, Simoens S, Wasem J, Boyer L, Dussart C, Auquier P.   +9 more
europepmc   +1 more source

Financial reimbursement for clinical trial participation costs: a pilot feasibility study. [PDF]

JNCI Cancer Spectr
Williams CP, Henderson NL, Jahan N, Stringer-Reasor E, Azuero A, Pisu M, Arend RC, Rocque GB.   +7 more
europepmc   +1 more source

Validation of Parkinson's Disease Diagnoses in a National Register: Accuracy, Limitations, and Utility. [PDF]

Clin Epidemiol
Räty V, Kuusimäki T, Vahlberg T, Tolppanen AM, Kaasinen V.   +4 more
europepmc   +1 more source

Financial influences and the primacy of patient welfare - an empirical and ethical analysis in German cancer medicine. [PDF]

BMC Med Ethics
Koenig JFL, Aufenberg B, Brei G, Reitmayer S, Sommerlatte S, Greiner W, Schildmann J, Winkler EC, Mehlis K.   +8 more
europepmc   +1 more source

Assessing Eligibility for Anticancer Drug Health Insurance Reimbursement Using Large Language Models: Benchmark Development and Comparative Study. [PDF]

J Med Internet Res
Seo J, Kim T, Kim JH.
europepmc   +1 more source

Reimbursement [PDF]

, 2020
openaire   +1 more source

Financial Feasibility of BPaL(M) Under Pretomanid Price Scenarios - China, 2023-2024. [PDF]

China CDC Wkly
Ren J, Wang N, Zhu H, Nie W, Sun F, Xiong Y, Fu L, Luo H, Cheng S, Zhao Y, Huang F.   +10 more
europepmc   +1 more source